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About 100 million dengue cases are reported annually and an estimated 2.5 billion 
people are susceptible to the infection mostly in the tropical regions. Dengue virus is a 
member of the Flavivirus genus and consists of four serotypes (DV-1, DV-2, DV-3, and DV-
4), each of which is capable of causing dengue fever and the more severe dengue 
hemorrhagic fever or dengue shock syndrome. There is an urgent need to develop a safe and 
effective vaccine that induces protective immune response to all the four serotypes 
overcoming antibody dependent enhancement. At present there is no licensed vaccine or 
specific therapeutic measures for prevention or management of the fatal infection. This mini 
review outlines the different vaccine candidates that are at various stages of development.  
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In the last 20 years dengue has spread rapidly and is endemic in more than 100 
countries. Dengue virus infection represents a major, growing public health problem with an 
estimated 2.5 billion people at risk of infection in tropical and subtropical countries (WHO, 
2009). Early reports on dengue fever outbreaks date back to about two hundred years ago but in 
recent times the major burden of the fatal disease are borne particularly in south east Asia, 
south and central America (Whitehead et al. 2007; Cardosa, 1998). Dengue Fever is a debilitating 
and often fatal flavivirus infection transmitted by Aedes mosquitoes (Edelman, 2007). There are 
more than 100 million cases of dengue infections annually and about half a million reports of 
the more severe and threatening dengue haemorrhagic fever (DHF) and dengue shock 
syndrome (DSS) (Gubler, 2002a, 2002b). There are four serotypes of dengue virus (DV1, DV2, 
DV3 and DV4). All the serotypes are competent in causing asymptomatic manifestations as well 
as the more severe and fatal DHF and DSS. Dengue virus comprises if a single-stranded, 
positive-sense RNA genome. Translation of the viral RNA results in a single polypeptide that is 
processed by proteases, generating three structural proteins and seven non-structural (NS) 
proteins (Lindenbach and Rice, 2001; Clyde and Harris, 2006). The structural proteins consists of 
the capsid, membrane and the envelope where as the non structural proteins are NS1, NS2A, 
NS2B, NS3, NS4A, NS4B and NS5. There is also a membrane precursor (prM), which assists in 
the folding of the envelope protein. The Envelope protein plays an important role in infection of 
the cells and is also reported to be the target to develop neutralizing antibodies 
(Mukhopadhyay et al. 2005; Halstead, 1989).  
Advaita Ganguly et al. / Research in Pharmacy 3(2): 18-25, 2013 
 
19 
 
 Dengue has become a huge burden both in terms of lives lost particularly children and 
also the economic setback to the emerging economies of the world to contain the disease. A 
primary infection with any of the serotypes would induce lifetime immunity against that 
particular serotype but a subsequent infection with a different serotype can increase the severity 
of the disease due to a phenomenon known as antibody dependent enhancement (ADE). Hence 
development of an effective vaccine candidate catering to all the four serotypes, which would 
be safe and cost effective, is of great significance particularly for children and young adults who 
are the most susceptible (Jin, 2009). Currently there are no licensed vaccines available for 
dengue although there are vaccines available for a number of closely related viruses. The World 
Health Organization has prioritized the development of dengue vaccine and therapeutics for a 
long time. But so far due to unsuccessful development of any kind of vaccine or treatment for 
containing dengue, the arrangements so far pursued have been vector control and individual 
preventive steps which are tough to sustain and also expensive (Brandt, 1990; Stephenson, 
2006). The foremost issue associated with dengue vaccine development is the need for 
concurrent protective immunity against all four serotypes due to ADE (Guzman et al. 2007; 
Kliks et al. 1989; Morens and Halstead, 1990). This short article summarizes various approaches 
undertaken towards a successful dengue vaccine and the challenges associated with it. 
 
VACCINES: EFFORTS AND CHALLENGES 
With the ever-increasing severity of the dengue virus and its crucial impact on loss of life, 
economics of the endemic region etc., the need of an effective vaccine is becoming more and 
more significant (Malabadi, 2008; Malabadi et al. 2010, 2011). The increase in dengue incidence 
in the past decade and the simultaneous presence of four different serotypes has posed a greater 
threat to the communities and has also witnessed higher volumes of the more severe forms of 
dengue infection. The development of an effective dengue vaccine has been not easy although 
focused and concerted efforts have been made for the past 70 years. Just after the end of World 
War II, Sabin and colleagues reported one of the first formulations of a dengue vaccine. Their 
work was based on live attenuated virus passaged multiple times in the mouse brain (Sabin and 
Schlesinger, 1945; Sabin, 1952). After about 15 passages in the mouse brain, the virus became 
attenuated enough for trial in humans (Edelman, 2007; Jin et al. 2009). Much later Halstead and 
coworkers made efforts by attenuating dengue virus in dog kidney cells (Thomas and Endy, 
2011). Other developments are focused on inactivated and subunit virus candidates (Whitehead 
et al. 2007). The major hindrance faced by researchers in vaccine development is the 
phenomenon of Antibody dependent enhancement (ADE). The presence of non-neutralizing 
antibodies developed during a primary infection of dengue greatly increases the severity of a 
second dengue infection with a different serotype by formation of immune complexes or 
facilitating viral access to Fcγ-Receptor possessing cells (Calvert et al. 2006; Halstead, 2003). 
Therefore an ideal vaccine candidate should be able to circumvent the ADE phenomenon and 
be tetravalent in nature or a combination of four monovalent vaccines delivered as a single 
vaccine. The vaccine should also be able to confer immunity against all the four different 
serotypes. Also the need to understand the underlying molecular principles that govern 
pathogenesis of dengue is very important (Murrrel et al. 2011). Currently, though over the past 
decade efforts have been more aggressive to develop an effective intervention to the fatal 
infection with the advent of recombinant DNA technology. There are many targeting 
approaches and the development of  nanocarrier vaccine  have been reviewed  (Khan et al. 2011, 
2012).  The absences of a proper animal system to test the vaccine candidates have also been a 
deterrent in dengue vaccine research. Emerging economies of the world bear the greatest 
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burden of dengue fatality so an economically affordable vaccine is necessary which would 
Envelope glycoprotein that is part of the virus structure is considered a major target for vaccine 
research. Its functionality includes virus attachment and subsequent cell entry. Domain III of 
the envelope protein is considered most important owing to its role in cell receptor binding 
(Lok et al. 2008). Other proteins such as the membrane and NS1 are also thought to be protective 
(Schlesinger et al. 1986). Monoclonal antibodies against Envelope and pre membrane proteins 
have been efficient in protecting against severe infection (Crill and Roehrig, 2001). There is also 
evidence that protective anti dengue antibodies are effective in children with maternal 
inheritance. Cell mediated immune responses have also been shown to play a role in active viral 
clearance (Samuel and Diamond, 2006).  
 Live attenuated vaccine development efforts are considered one of the effective 
approaches. A wild type dengue virus can be attenuated by serial passages in tissue culture to 
be used in humans maintaining its ability to generate an immune response. In another 
embodiment a chimeric vaccine candidate is generated by modification of a licensed yellow 
fever virus vaccine with dengue proteins. Another important feature of a live attenuated 
vaccine is its ability to induce sustained immune responses very closely mimicking a response 
incase of a natural infection. Sanofi Pasteur has developed a chimeric vaccine based on the 
yellow fever vaccine by incorporating dengue premembrane and envelope genes of dengue 
(Guy and Almond, 2007; Murphy and Whitehead, 2011). Recently, efficacy trial of the vaccine in 
Thailand demonstrated impressive safety profile along with the ability to protect against three 
of the four-dengue serotypes. Further clinical trials are underway to validate vaccine efficacy 
and safety (www.sanofipasteur.com).  Inactivated virus vaccines are also in preclinical stages of 
development and one of the dengue serotype 2 vaccines manufactured by the Walter Reed 
Army Institute for Research is scheduled to begin clinical trials shortly.   Inactivated vaccines 
have certain advantages over the attenuated ones including inability to become pathogenic and 
also being able to induce immune response in all four dengue serotypes due to immunogenic 
equality (Whitehead et al. 2007). Recombinant subunit vaccine candidates have also been 
developed primarily based on the envelope protein. There has been a study by the Pedro Kouri 
Tropical Medicine Institute where the domain III of the envelope protein was fused with a 
carrier protein and monovalent constructs were made for all the four serotypes. Each of the 
constructs was able to induce neutralizing immune response and also demonstrated protection 
against viral challenge (Hermida et al. 2006). Another bivalent effort is based on a domain III 
and STF2D fusion protein conjugate. There is also a tetravalent conjugate of Domain III and 
Ag473 fusion protein being evaluated in animals (Das et al. 2009). A lot of Dengue vaccine 
efforts based on virus like particles (VLP) are in preclinical phases. Viruses like particles lack 
replication material but are able to mimic antigen presentation like a natural viral infection 
(Jennings and Bachmann, 2008). A tetravalent vaccine candidate have been developed by Cytos 
Biotechnology by chemically attaching envelope domain III to an E.coli expressed VLP. Another 
monovalent candidate has been in development in ICGEB, India where the basis is the envelope 
domain III and P. pastoris expressed VLP (Schmitz et al. 2011). The Carolina vaccine Institute 
(CVI) has been a pioneer in the development of a alpha virus replicon vector expressing 
envelope protein. This strategy was demonstrated by immunizing monkeys resulting in the 
generation of neutralizing antibodies and protection from viral challenge as well. GenPhar Inc., 
developed bivalent vaccine candidates based on an adenovirus construct. Challenge studies 
resulted in absolute protection against dengue type 1 and 3 whereas significant reduction in 
viremia was observed against type 2 and 4.  Another strategy adopted by the Pasteur Institut is 
centered on a tetravalent dengue antigen from a live attenuated measles vaccine vector. The 
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construct expresses domain IIIs of all the four serotypes along with the membrane protein 
ectodomain. Analysis in murine models showed induction of neutralizing antibodies against all 
the serotypes. Clinical trials of the construct have been planned in the near future (Schmitz et al. 
2011).  With genetic engineering and recombinant technology rapidly making progress, concept 
of DNA vaccines have been gaining considerable momentum. Studies have been conducted 
with monovalent constructs of dengue in macaques that resulted in production of neutralizing 
antibodies. It also conferred protection to the vaccinated macaques when challenged with a 
wild type dengue virus strain (Raviprakasha et al. 2000).  A follow up study was done by the 
same research group, to enhance the neutralizing efficiency of the earlier DNA vaccine 
construct. Neutralization efficiency increased significantly from the earlier construct and was 
stable for 6 months post vaccination. All the monkeys barring one were also completely 
protected from a virus challenge (Raviprakasha et al. 2000; Konishi et al. 2006). These important 
findings led to the transition of DNA based dengue vaccines towards clinical trial (Danko et al. 
2011). Advantages of DNA based strategies involve its ability to induce both humoral and cell 
mediated immune responses, lack of complicity like other vaccine approaches and technically 
simpler to develop. On the contrary there are also some drawbacks associated like the level of 
immunogenicity obtained from clinical studies have been slightly low. Another limitation is 
that of insufficient cell uptake (Murrrel et al. 2011) leading to reduced protein expression. 
Nonetheless, promising DNA based strategies are being explored at preclinical and clinical 
phases with varied outcomes.  Further studies on DNA based vaccination including design, 
adjuvant selection, delivery methodology are needed to overcome the current limitations as it 
has the potential of being an effective strategy to counter dengue and other infectious agents 
owing to being cost effective, technically easier to manufacture, stability and the ability to 
deliver multiple agents in one single construct. 
 
TARGETING STRATEGIES FOR DENGUE: A VIABLE ALTERNATIVE 
Dendritic cells (DCs) are a unique class of antigen presenting cells that have an important role 
in both innate and cell mediated immunity. DCs have significant role in the activation of T- and 
B-cell immune responses and are deemed to be more efficient than other antigen presenting 
cells. Targeting of DCs via the surface receptors may be an alternative strategy for development 
of low dose targeted dengue vaccines. DC targeting greatly enhances antigen delivery efficiency 
to the DCs than traditional vaccination methods wherein enzymes and other cells might have 
adverse exposure before being taken up by the DCs (Wang et al. 2009; Tacken et al. 2006). DCs 
internalize antigens using its many cell surface receptors including Gb3, CD40, Fc receptors, C-
type lectin receptors etc and present them to both MHC I and II pathways (Figdor et al. 2002; 
Tacken et al. 2007). A lot of studies have been conducted on DC cell receptors and antigen 
targeting. DEC-205 is a part of the C-type lectin receptor family that has been extensively 
studied. It is present on both mature and immature dendritic cells and targeting DEC-205 
results in improved cross-presentation of antigens compared to other receptors (Bozzacco et al. 
2007; Jiang et al. 1995; Banchereau and Steinman, 1998). Reports illustrate that DEC-205 
targeting resulted in improvement in antigen presentation efficiency to T-Cells (Wang et al. 
2005). We have developed bispecific antibody based delivery vector to target DCs with biotin 
labeled antigens that could be proteins, DNA, peptides, gangliosides etc. (45, Wang et al. 2005). 
In this strategy, the antibody has dual specificity i.e. one arm can bind to any biotinylated 
antigen and the other arm is specific to the DC receptor DEC-205. Targeting resulted in 
reduction in antigen dosage by approximately 500 fold when compared with non-targeted 
antigens. Animal studies demonstrated targeted strategy along with co-stimulatory anti-CD40 
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monoclonal antibody significantly enhanced both humoral and adapted immune responses for 
SARS-CoV, Ebola GP1, MUC-1 peptide (Wang et al. 2009). Another study targeting mucosal 
DCs in murine model with SARS NP DNA induced strong immune response. When CD40 
monoclonal antibody as a DC maturation stimuli was used, the responses were improved 
considerably. Dengue specific DC targeted vaccine candidates are currently investigated 
(unpublished data). DC targeted systems involving bispecific antibodies could be potentially a 
viable alternative for the development of dengue vaccines which have been long overdue 
(Bonifaz et al. 2004; Malabadi et al. 2012) Exhaustive research on alternative approaches needs to 
be done to come up with potent strategies to counter dengue fatalities that have so far taken 
millions of lives around the world. 
 
 
Fig: Schematic representation of DC Targeted Strategy 
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